Depression treatments can ease symptoms, but they often come with side effects that affect daily life, relationships, and overall well-being. Some fade with time, while others become long-term challenges. Understanding what to expect helps you make informed choices, speak up when something feels wrong, and avoid mistaking side effects for new symptoms.

Most Common Side Effects of Antidepressants

Antidepressants are widely prescribed. They work by adjusting brain chemicals like serotonin and norepinephrine, improving mood but sometimes affecting sleep, appetite, digestion, and sexual health.

Common Side Effects of SSRIs and SNRIs

• Sexual Dysfunction: Sexual side effects are among the most frequently reported and most bothersome during SSRI or SNRI treatment. Studies show that between 58% and 73% of patients on SSRIs experience some form of sexual dysfunction, including reduced libido, delayed orgasm, anorgasmia, and erectile difficulties (1). Paroxetine is consistently associated with the highest rates of these issues (1, 2). Recovery is often slow, with symptoms persisting in most patients after several months (2)..
• Gastrointestinal Issues: Nausea occurs in up to 26% of patients,usually appearing within the first two weeks.. Diarrhea and decreased appetite are also common (3).
• Drowsiness and Fatigue: Drowsiness is reported as bothersome by 17% of SSRI users (4). It often appears early in treatment and may linger for weeks, especially with drugs like paroxetine and fluvoxamine (4, 5).
• Weight Gain: Can develop with long-term SSRI use, particularly paroxetine, and may contribute to stopping medication. (6).
• Movement Disorders: Antidepressant-induced movement disorders, Though less commonly, tremors, akathisia, bruxism, and tardive dyskinesia are real risks, with bruxism and tremors being the most frequently reported. (7).

Note: Studies show physicians often underestimate both the frequency and the impact of these effects. Open communication is key. No one should feel forced to tolerate unmanageable side effects.

How Do Depression Treatments Affect Emotional Health?

For many patients, the emotional changes that follow aren’t always positive. Some describe feeling emotionally flat or disconnected, even as their core symptoms improve. This isn’t lingering sadness. It’s a shift in how emotions are felt, expressed, or sometimes not felt at all. 

For some, motivation fades. For others, once-familiar emotions become blunted. These effects are common, complex, and not always easy to separate from the depression itself.

Common emotional impacts include:

• Emotional Blunting: Nearly half of patients report feeling emotionally numb or detached. This blunting can coexist with residual depression, complicating treatment. (8)
• SSRI-Associated Apathy Syndrome: Research suggests SSRIs may contribute to loss of motivation and emotional engagement. (9)
• Positive Emotional Processing Shifts: On the other hand, SSRIs can reduce negative emotional bias early in treatment, sometimes predicting future recovery. (10)

In some cases, these emotional side effects resolve with dose changes or switching medications. In others, patients may benefit from TMS or psychotherapy to help re-engage the emotional centers of the brain. Real healing means regaining full emotional range without feeling overmedicated or numb.

Therapy Side Effects

Like any treatment, therapy may also come with side effects. 

• Negative Effects: 15% of outpatients and 37% of inpatients report side effects such as emotional strain, worsening symptoms, or dependence on the therapist (11).
• Serious Concerns: 7% of outpatients and 29% of inpatients experienced malpractice or unethical behavior. Though rare, breaches of confidentiality and abuse were reported in under 1% of cases (11).
• Risk Factors: Younger patients, strained relationships, or poor therapist matches increase the likelihood of negative experiences (11).

Therapy is powerful, but outcomes may vary. Monitoring the process is as important as monitoring medication.

Risks and Side Effects of TMS Therapy

Transcranial Magnetic Stimulation (TMS) has an excellent safety profile when delivered within clinical guidelines. As Dr. Sarah Lisanby, Director at the National Institute of Mental Health, emphasizes, “The serious side effects are rare, and the most serious known side effect is a seizure.” Fortunately, the risk of seizure is extremely low. Estimated at fewer than 0.2 per 1,000 sessions in properly screened patients. “Seizure can be prevented in various ways,” says Dr. Lisanby, “through adequate screening, accurate motor threshold determination, and proper dosage selection.” (12)

The most common side effects include headache, reported in 32–36% of patients, scalp discomfort, and facial muscle twitching, all of which typically decrease over time. Hearing changes are preventable with earplugs, which must be used consistently. “Properly inserted earplugs must be used at all times by subjects and by the operator to protect hearing,” Lisanby notes.

TMS has not been associated with cognitive decline, long-term hearing loss, or systemic side effects in clinical trials, making it a viable, evidence-based option for treatment-resistant depression.

What About ECT or Ketamine? Are There Side Effects Worse?

Electroconvulsive Therapy (ECT): Temporary headache, nausea, and muscle soreness are common. Memory issues, especially retrograde amnesia, are the most concerning but usually resolve for most patients. (13)

Ketamine/Esketamine: Rapid relief but may cause dissociation, confusion, elevated blood pressure, or agitation. Long-term risks are still under study, and treatment requires medical supervision due to misuse potential. (14)

Deciding What’s Worth It

To judge whether to continue a treatment:

• Track the timeline: Side effects that peak within the first two weeks often resolve. If they last beyond six to eight weeks, they may not go away on their own.
• Assess your quality of life: Ask yourself if the benefits outweigh the side effects. Is life better overall, or just different? 
• Watch for warning signs: Weight gain, sexual dysfunction, and emotional blunting should not be ignored as they may affect long-term wellness.
• Stay informed: Some medications cause withdrawal effects if stopped too quickly. Others interact with common supplements. Educating yourself reduces surprises.

Why Choosing the Right TMS Center Makes a Big Difference

TMS is safe and effective, but the outcome depends heavily on who is guiding the treatment. Not all TMS clinics operate the same way. 

A quality TMS center will provide:

• Certified TMS physicians on-site – Your treatment is evaluated and adjusted by someone trained in psychiatry and neuromodulation. 
• Custom protocols based on your condition – Depression, PTSD, OCD, and anxiety all respond differently. Your care should reflect that.
• Ongoing clinical supervision – Real doctors remain involved during the full course of treatment. Adjustments are made in real time, based on how your brain is responding.
• Safety standards that meet medical guidelines – From seizure screening to follow-up support, nothing is left to chance.
• Outcome tracking – Your progress is monitored through clinical scales. If something needs to change, it changes fast.

Choosing the wrong center may delay progress, increase relapse risk, or lead to unnecessary frustration. The right TMS doctor listens, evaluates, and adapts treatment based on actual clinical need.

Get Real, Physician-Led Help at the TMS Institute of Arizona

Your care deserves expertise, attention, and precision from professionals who understand the brain.

The TMS Institute of Arizona is led by certified physicians with advanced training in neuromodulation and depression care. We work with patients facing complex, treatment-resistant depression. Whether you’ve gone through multiple medications or felt dismissed by other providers, we take your case seriously. Every treatment plan is built around clinical evidence and real patient data.

TMS works best with accuracy, consistency, and close supervision. That means the right brain region, the right settings, and the right adjustments along the way. Our center is based in Scottsdale, Arizona. For those searching for TMS in Scottsdale Arizona or looking for a trusted TMS doctor in Arizona, this is where real care begins. No shortcuts. No pressure. Just medically grounded support from start to finish.

Contact us today and speak directly with a physician. You’ll be heard. You’ll be evaluated with care. You’ll know you’re in the right hands.

References

1. Montejo. (2023). Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. The Journal of Clinical Psychiatry, 62 Suppl 3. https://pubmed.ncbi.nlm.nih.gov/11229449/
2. Montejo-gonzàlez, A. L., Llorca, G., Izquierdo, J. A., Ledesma, A., M. Bousono, Calcedo, A., Carrasco, J. L., J. Ciudad, Daniel, E., De, J., J. Derecho, Franco, M., Gomez, M. J., Macias, J. A., Martin, T., Perez, V., Sanchez, J. M., Sanchez, S., & Vicens, E. (1997). Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. Journal of Sex & Marital Therapy, 23(3), 176–194. https://doi.org/10.1080/00926239708403923
3. Trindade. (2019). Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ : Canadian Medical Association Journal = Journal de l’Association Medicale Canadienne, 159(10). https://pubmed.ncbi.nlm.nih.gov/9861221/
4. Hu, X. H., Bull, S. A., Hunkeler, E. M., Ming, E., Lee, J. Y., Fireman, B., & Markson, L. E. (2004). Incidence and Duration of Side Effects and Those Rated as Bothersome With Selective Serotonin Reuptake Inhibitor Treatment for Depression. The Journal of Clinical Psychiatry, 65(7), 959–965. https://doi.org/10.4088/jcp.v65n0712
5. Boyer WF;Blumhardt CL. (2025). The safety profile of paroxetine. The Journal of Clinical Psychiatry, 53 Suppl. https://pubmed.ncbi.nlm.nih.gov/1531828/
6. Fava M. (2025). Weight gain and antidepressants. The Journal of Clinical Psychiatry, 61 Suppl 11. https://pubmed.ncbi.nlm.nih.gov/10926053/
7. Revet, A., François Montastruc, Roussin, A., Raynaud, J.-P., Maryse Lapeyre-Mestre, & Thu, T. (2020). Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database. BMC Psychiatry, 20(1). https://doi.org/10.1186/s12888-020-02711-z
8. Goodwin, G. M., Price, J., C. De Bodinat, & Laredo, J. (2017). Emotional blunting with antidepressant treatments: A survey among depressed patients. Journal of Affective Disorders, 221, 31–35. https://doi.org/10.1016/j.jad.2017.05.048
9. Padala, P. R., Padala, K. P., Majagi, A. S., Garner, K. K., Dennis, R. A., & Sullivan, D. H. (2020). Selective serotonin reuptake inhibitors-associated apathy syndrome. Medicine, 99(33), e21497–e21497. https://doi.org/10.1097/md.0000000000021497
10. Godlewska, B. R., Browning, M., Norbury, R., Cowen, P. J., & Harmer, C. J. (2016). Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression. Translational Psychiatry, 6(11), e957–e957. https://doi.org/10.1038/tp.2016.130
11. Gerke, L., Ann-Katrin Meyrose, Ladwig, I., Rief, W., & Nestoriuc, Y. (2020). Frequencies and Predictors of Negative Effects in Routine Inpatient and Outpatient Psychotherapy: Two Observational Studies. Frontiers in Psychology, 11. https://doi.org/10.3389/fpsyg.2020.02144
12. Sarah H. Lisanby: Transcranial Magnetic Stimulation Safety and Risk. (2020, April 28). National Institute of Mental Health (NIMH). https://www.nimh.nih.gov/news/media/2020/sarah-h-lisanby-transcranial-magnetic-stimulation-safety-and-risk
13. Andrade, C., Shyam Sundar Arumugham, & Jagadisha Thirthalli. (2016). Adverse Effects of Electroconvulsive Therapy. Psychiatric Clinics of North America, 39(3), 513–530. https://doi.org/10.1016/j.psc.2016.04.004
14. Mani Yavi, Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022). Ketamine treatment for depression: a review. Discover Mental Health, 2(1). https://doi.org/10.1007/s44192-022-00012-3